Skip to Content
Søg Menu

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

Interview: The effectiveness of avelumab is consistent with the results of the JAVELIN Bladder 100 study.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostatacancer Play the Video 18:34

Highlights From the Nordic Urothelial Cancer Oncology Group (NUCOG)

/ Katrine Ørum / Helle Pappot / Anders Ullén
Blærecancer

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Nyrecancer
Dag Stormoen

Immunterapi og antibody-drug conjugates vil få en central plads i fremtidens behandling af blærecancer

/ Dag Rune Stormoen
ASCOGU25Blærecancer Play the Video 04:20
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blærecancer Play the Video 08:59

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatacancer

Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma

/ Martin Zarba / Jan Andreasen
ASCOGU25Nyrecancer
Philippe Barthélémy

Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

/ Philippe Barthélémy
ASCOGU25 Play the Video 03:28
Petros Grivas

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

/ Petros Grivas
ASCOGU25Type 2-diabetesBlærecancer Play the Video 02:42

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top